The fact that an angiotensin converting enzyme inhibitor is able to inhibit left ventricular dilatation in patients with ventricular dysfunction following myocardial infarction has been well established by animal experiments and clinical trials (27,28). The gene discussed is ACE; the disease is Left ventricular dilatation.